Veltassa and Stroke - a phase IV clinical study of FDA data

Summary:

Stroke is reported as a side effect among people who take Veltassa (patiromer sorbitex calcium), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Eliquis, and have Hyperkalemia.

The phase IV clinical study analyzes which people have Stroke when taking Veltassa. It is created by eHealthMe based on reports of 15,647 people who have side effects when taking Veltassa from the FDA, and is updated regularly.

What is Veltassa?

Veltassa has active ingredients of patiromer sorbitex calcium. eHealthMe is studying from 15,649 Veltassa users. Check the latest studies of Veltassa.

What is Stroke?

Stroke (sudden death of a portion of the brain cells due to a lack of oxygen) is found to be associated with 2,340 drugs and 3,028 conditions by eHealthMe. Check the latest studies of Stroke.

On Jun, 14, 2026

15,647 people reported to have side effects when taking Veltassa.
Among them, 140 people (0.89%) have Stroke.

Among these 140 people:

* Approximation only. Some reports may have incomplete information.

Do you take Veltassa and have Stroke?

- Check whether Stroke is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Veltassa:

Veltassa (15,649 reports)

Stroke treatments and more:

Stroke (334,635 reports)

How severe was Stroke and when was it recovered:

Stroke in Veltassa

Expand to all the drugs that have ingredients of patiromer sorbitex calcium:

Stroke and drugs with ingredients of patiromer sorbitex calcium (141 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Veltassa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Stroke:

Stroke (2,340 drugs)

Browse all the conditions that are associated with Stroke:

Stroke (3,028 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on patiromer sorbitex calcium (the active ingredients of Veltassa) and Veltassa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.